Thalidomide has been reported to be an effective agent for treatment of chronic graft-versus-host disease (CGVHD). To determine the efficacy of this agent in patients with refractory CGVHD a total of 80 patients who failed to respond to prednisone (PSE) or PSE and cyclosporine (CSA) were treated with thalidomide. Sixteen patients (20%) had a sustained response, 9 with a complete remission and 7 with a partial response. Twenty-nine patients (36%) had thalidomide discontinued because of side effects, which included sedation, constipation, neuritis, skin rash, and neutropenia.
Side effects were reversible with drug discontinuation except for mild residual neuritis in one case. Rashes and neutropenia have not previously been reported as thalidomide side effects when used for CGVHD treatment. We conclude thalidomide is immunosuppressive and active in the treatment of CGVHD. A high incidence of reversible side effects limited dose intensity and reduced the number of patients who could benefit from treatment.
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PUVA had complete remissions. An additional 21 patients received thalidomide as part of primary therapy for newly diagnosed poor-risk CGVHD. Seven of these had a complete response (CR). Toxicity appeared to be minimal and was limited to sedation and constipation, or sensory neuropathy reversible with discontinuation of medication.
To extend the experience with this medication we have performed a phase I1 trial of thalidomide as salvage treatment for CGVHD refractory to primary therapy with PSE alone or in combination with CSA. This report summarizes results of treatment in 86 patients.
PATIENTS AND METHODS
All patients signed informed consent forms approved by the Institutional Review Boards of the City of Hope National Medical Center and Stanford University. All female patients consented to take birth control pills while on thalidomide.
Patients. Between September 1987 and January 1994, 86 patients (27%) from a total of 318 who developed CGVHD were enrolled at both institutions on this study. Six patients were not evaluable. The reasons were as follows: 4 died 5 to 13 days from starting thalidomide from interstitial pneumonia with severe refractory CGVHD (n = 3), and from Candida sepsis (n = l ) ; 1 patient responded but CSA had also been started for CGVHD 1 I days earlier; and 1 patient stopped thalidomide after 10 days of therapy because of anxiety over possible future side effects. The characteristics of the 80 evaluable patients are listed in Table l . All patients had undergone allogeneic BMT from HLA identical siblings or matched unrelated donors for hematologic malignancies, aplastic anemia, o r thalassemia. The preparative regimens varied according to disease and remission status and have been reported elsewhere.""' These included fractionated total body irradiation (1,320 rad) with either cyclophosphamide 120 m g k g or etoposide 60 mgkg, o r busulfan 16 mgkg with cyclophosphamide 120 mgkg. T depletion was not used. Acute GVHD prophylaxis varied over time according to institutionally active protocols and included CSA and PSE, CSNmethotrexate (MTX)/PSE, and Xomazyme/CSA/PSE.' ',IJ All patients on these GVHD protocols were scheduled to continue CSA with or without PSE until day 180 after BMT.
Diagnosis. The diagnosis of CGVHD was made according to standard clinical criteria.'.''.'" The diagnosis was confirmed histologically except in cases of mouth CGVHD or when liver or lung biopsies were necessary and the responsible physician did not feel coagulation parameters were safe. Twenty-two patients did not have a biopsy to confirm the CGVHD histologically.
All patients had extensive CGVHD (generalized skin, liver involvement with hyperbilirubinemia, or advanced histologic changes, or multiple organ CGVHD) according to previously published criteria.2 Thirty-eight of the 80 patients also were classified as having poor prognostic features or high risk due to either thrombocytopenia, progressive presentation, or combined skin and liver CGVHD. Eligibility. Patients were eligible if they had progressing CGVHD after 1 month (n = 31) or stable but unimproved CGVHD (n = 40) after 2 months of PSE or PSElCSA treatment. Patients who responded to PSE or PSElCSA but flared when these were tapered and required maintaining PSE at doses 220 mg/d were also eligible (n = 7). Patients were also eligible for thalidomide at PSE doses 520 mg/d if CGVHD was present and ongoing PSE treatment was contraindicated due to steroid related complications (aseptic hip necrosis, prior or concurrent fungal infections, or intolerance of cushingoid effects) (n = 2). Prior CSA therapy was not required but most patients had failed CSA (n = 67) as well and had thalidomide added to their existing PSWCSA treatment or were unable to receive further CSA because of CSA-related end-organ toxicity (n = 13) ( Table 2 ). The target protocol eligibility dose of PSE 20 mg/d was chosen taking into account the long period of time these patients need to be on therapy for CGVHD with the potential for longterm steroid related complications. The median time on therapy for CGVHD before thalidomide was started was 4.5 months (range, 1 month to 3 '/z years).
Thalidomide. Thalidomide was obtained either from Reiza do Nordeste (Sao Paulo, Brasil) or Grunenthal GMBH (Stolberg, Germany). Thalidomide was started at a dose of 100 mg orally four times a day and if no side effects were encountered was escalated to 200 and 300 mg four times a day. Drug levels were not evaluated for thalidomide. CSA levels were also not routinely done in all patients with CGVHD and their influence on outcome was therefore not analyzed in this trial. Patients were maintained on PSE and CSA 3605 when started on thalidomide. PSElCSA were then slowly tapered if CGVHD improved with addition of thalidomide.
Responses. The frequency of follow-up for patients on thalidomide was determined by physician assesment of clinical need. Retrospective chart review was used to determine outcome. A complete response was classified as complete disappearance of all clinical manifestations of CGVHD. A partial response included a 50% improvement in objective parameters of CGVHD manifestations (extent of skin involvement, total bilirubin, pulmonary function tests (PIT) in bronchiolitis obliterans with organizing pneumonia [BOOP]). A response in oral CGVHD was more difficult to quantitate objectively but required symptomatic improvement as well as physician assessment of comparative improvement. Patients were considered to have no response if CGVHD progressed after 1 month or failed to improve after 3 months of thalidomide therapy. Only patients with sustained responses to thalidomide without reprogression were included among the responders. Patients who responded but then had to discontinue the drug due to side effects were considered treatment failures if the disease then progressed. All patients in this report have been on protocol more than 3 months. Survival was analyzed from the start of thalidomide therapy.
RESULTS

Response.
Eighty patients are evaluable for response and toxicity. Their characteristics at transplant, acute GVHD pro- phylaxis regimen, and grade of subsequent acute GVHD are summarized in Table l . The status of their CGVHD at entry to the thalidomide protocol is summarized in Table 2 .
Sixteen of 80 patients (20%) had a sustained response (Table 3) . Nine patients had a CR and seven a partial response (PR). Overall 6 (16%) of 38 patients with high-risk CGVHD and 10 (24%) of 42 with standard-risk CGVHD responded to thalidomide ( Table  4) . The high-risk group and 4 with thrombocytopenia with mouth (n = 1) or liver (n = 3) involvement. None of 12 patients with combined skin and liver CGVHD responded. Four of 15 patients with mouth only CGVHD and 5 of 14 with combined skin and mouth CGVHD responded. One of these latter patients had a PR for severe sclerodermatous skin involvement. No other patient treated for severe sclerodermatous skin involvement (isolated or with other organ involvement) responded. One other patient with combined mouth and skin CGVHD had a PR for the mouth CGVHD on thalidomide without improvement of skin manifestations. The latter then improved on additional PUVA therapy. Five of 15 with liver CGVHD with or without associated mouth CGVHD (total bilirubin median 11.6, range 4.9 to 25.1) responded. One other patient with a PR for mouth CGVHD also had BOOP with PFT at 60% of pre-BMT values and was oxygen dependent at start of thalidomide. Her PFT only improved by 20% on thalidomide and did not meet criteria for a PR, but she became oxygen independent and her exercise tolerance improved. Unfortunately, she died of an acute encephalitis of presumed viral origin after remaining 2 years on thalidomide treatment. None of the other eight patients with BOOP treated with thalidomide responded. Five patients with gastrointestinal (GI) CGVHD were treated with thalidomide (Table 2) . One had esophageal web syndrome. The other four had lower GI CGVHD. All had additional other organ involvement (skin/mouth/liver). They were placed on thalidomide with the intent of testing if the constipating effect of the drug would allow for absorption and a therapeutic effect even in the setting of diarrhea from CGVHD. None of these patients became responders.
Fifteen of the 16 patients with refractory CGVHD who responded to thalidomide had failed PSE and CSA, one responding patient with mouth only CGVHD was on PSE only because of CSA intolerance. Among the 16 patients who responded to thalidomide the median time to achieve a PR was 3 months (range 1 to 12 months). The median duration of thalidomide therapy was 16 months (range 4 months to 4'12 years). The median thalidomide dose was 200 mg four times daily (range, 100 mg three times a day to 400 mg four times a day). One patient with a PR for skidmouth CGVHD who had no side effects with the 300 mg three times a day dose was dose escalated to 400 mg four times a day. All patients initially remained on PSE or PSE/CSA in addition to the thalidomide until a response was achieved and were then sequentially tapered off all three drugs over several months. The choice of drug to taper first was by physician preference although PSE was usually tapered first. Six of the 16 responders remain off all immunosuppressive medications 8 to 36 months after discontinuing thalidomide. Seven additional responding patients remain on tapered thalidomide or PSE and/or CSA for a median of 3 years (range, 1 to S years) from the start of thalidomide therapy. Three additional patients with a sustained response to thalidomide died while still on tapered doses of thalidomide, PSE/CSA from infectious complications of CGVHD (two due to pneumonia and one from encephalitis) 6, 16, and 2. 5 months from the start of thalidomide treatment.
An additional eight patients were improving on thalidomide but had to discontinue the drug because of side effects and then subsequently progressed. They were counted as treatment failures. Five had mouth CGVHD only, one had combined skidmouth, one combined mouth, esophageal web, and bronchiolitis, and one liver involvement. All flared again after discontinuation of thalidomide. Six remain with persistent unimproved CGVHD on PSE/CSA 1 to 5 years after discontinuing thalidomide. Two have had a PR, one with additional treatment, which included photopheresis with Of note one of the patients entered on this protocol had not received any CGVHD treatment for l year before starting thalidomide (Table 2) . She had sclerodermatous skin CGVHD with contractures and had developed a psychotic episode after 6 months of combined PSWCSA treatment. Both were tapered off and she remained with persistent CGVHD off therapy until thalidomide became available 1 year later. She died 2 months after starting thalidomide from CGVHD-related complications and was considered a treatment failure.
Toxicity. There was significant difficulty in maintaining patients on this medication because of a high frequency of both patient intolerance of sedation and bowel distension and additional side effects requiring drug discontinuation. Previous reports of side effects when using thalidomide for CGVHD have listed sedation and constipation as the most common with tachyphylaxis as treatment continues leading to adequate patient tolerance? Sensory neuropathy has also been reported as a less frequent complication but its appearance warrants taking the patient permanently off medication."
We also encountered frequent initial sedation and constipation (Table 4) . However, not all patients adapted with time and seven patients discontinued the drug due to persistent sedation even with dose reduction. Although constipation was less problematic resolving with stool softeners, the bowel distension caused by thalidomide led to stopping medication in three patients because of abdominal discomfort with nausea and vomiting. Symptoms of sensory neuropathy led to discontinuation of medication in three patients. One patient still has neuropathic symptoms 4 months after stopping thalidomide. Neuropathy resolved in the other two within 2 months of stopping medication.
We also encountered two additional side effects. The first was development of a new skin rash (in 4 patients) clinically suggestive of CGVHD (when none had been previously present) or flare of a pre-existing skin GVH rash (in 9 patients) within 4 weeks of starting treatment. PSWCSA doses had not yet been tapered in four (2 with and 2 without preexisting skin CGVHD) of these patients when the rash developed or flared. Skin biopsies were done in 5 of these 13 patients and showed histologic changes suggestive of CGVHD in all cases. In all cases improvement or resolution of skin rash occurred as PSE doses were increased at the same time that thalidomide was held. Two patients with skin CGVHD were rechallenged with thalidomide when the skin rash had improved and flared with the second challenge. Four other patients were not restarted on thalidomide after developing a rash due to physician andor patient reluctance to restart therapy due to this side effect. One patient who was started on thalidomide for skin (localized to face and upper torso) and mouth CGVHD developed a severe Stevens-Johnson like syndrome with erythroderma with bullous lesions and conjunctival and mouth mucosal involvement 2 weeks after starting therapy. His PSWCSA had not yet been tapered. He required hospitalization and high-dose steroids with resolution of the acute skin changes but persistence of his prior CGVHD baseline skin lesions. He subsequently died from CGVHD progression with BOOP but without new skin lesions. Seven other patients were restarted on thalidomide after the skin rashes improved and did not reflare. None of these became responders and were therefore eventually taken off medication because of CGVHD progression. Among the 13 patients who developed skin rashes with the start of thalidomide treatment there was a higher incidence of two poor risk factors. Six (46%) had prior thrombocytopenia and seven (54%) had progressive presentation of CGVHD. This compared with the 67 patients who did not develop skin rashes in which 23 (34%) had thrombocytopenia and 16 (24%) had progressive CGVHD. The third poor prognostic risk factor, combined skidiver CGVHD, was not more frequent in this group with only 1 of 13 (8%) in those developing a skin rash as opposed to 1 1 of 67 (16%) in those who did not.
The second additional unexpected toxicity was neutropenia (Table 4 ). This occurred in 14 patients at a median of 4 weeks (range 1 to 11 weeks) from starting therapy without affecting red blood cell (RBC) and platelet counts. The median pre-thalidomide white blood cell (WBC) count was 4.2 X IO9& (range, 1.6 to 6.4) with a median WBC nadir of 0.9 X IO9& (range, 0.3 to 2.0). The median thalidomide dose at which neutropenia developed was 200 mg four times a day (range, 50 mg twice a day to 300 mg four times a day). The neutropenia usually resolved within 1 month of discontinuing thalidomide (except in three patients who died between 3 weeks and 1 'l2 months from starting thalidomide due to refractory rapidly progressing CGVHD). As there are other causes of neutropenia in BMT patients, especially with CGVHD, six patients were rechallenged with thalidomide and again became neutropenic. The neutropenia was the direct reason for discontinuing thalidomide in 10 of 14 patients. In the other four patients, one had associated neuropathy and two others discontinued use due to refractory CGVHD. Only one patient who developed neutropenia remained on treatment. He had responded to thalidomide and was rechallenged and developed recurrent neutropenia, but was able to remain on 50% doses with intermittent G-CSF. Among the 14 patients who developed neutropenia 12 (86%) had thrombocytopenia, 8 (57%) had progressive CGVHD, and 3 (21%) had combined skidiver CGVHD. This compared with 14 (21%) with thrombocytopenia, 13 (20%) with progressive CGVHD, and 9 (14%) with combined skidiver CGVHD in the 66 patients who did not have neutropenia.
Survival and causes of death. Forty-three of the 80 (53%) treated patients are alive. Thirteen of sixteen (81%) patients who responded are alive with a median follow-up of 2 years/8 months (range, 6 months to 5 years). Thirty of 64 (47%) who did not respond survive with a median survival of l year12 months (range, 1 month to 7 years14 months).
Thirty-seven patients died. Twenty-seven died from organ failure with refractory CGVHD: 11 with hepatic failure, 6 with interstitial pneumonitis or respiratory failure associated with severe sclerodermatous or liver CGVHD, 10 with bronchiolitis obliterans. An additional 5 patients died from infection: two pneumonias, one disseminated aspergillus, one brain abscess, organism unidentified, and one encephalitis
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of presumed viral origin. One patient died from a cerebrovascular accident, one committed suicide 3 months off thalidomide with persistent liver CGVHD. Three patients died at home. Two were on thalidomide with severe sclerodermatous CGVHD. One was off thalidomide for 10 months with persisting CGVHD and severe immunodeficiency with disseminated mycobacterium avium-intracelulare infection. There were no relapses in these 80 patients with refractory CGVHD.
DISCUSSION
These results confirm thalidomide has activity against CGVHD, which has failed treatment with PSE or PSElCSA. Sixteen (20%) of 80 patients in this series had a sustained response. When looking at prognostic subgroups more responses were seen in patients with standard-risk CGVHD (10 of 42) than in those with high-risk disease (6 of 38). There was no particular risk profile that predicted which patients would respond except that responses were rare in those with CGVHD, which has had poor outcome with standard available treatment such as BOOP, combined skin and liver CGVHD, and progressive presentation. We did see responses in patients with thrombocytopenia as the only associated poor prognostic factor. Most of the responses were in patients with isolated mouth or liver CGVHD and skin involvement that did not include severe sclerodermatous manifestations. Thalidomide therapy was a new beneficial treatment modality for these patients since over half had a CR for CGVHD, which up to that point was refractory to treatment and all were able to either discontinue or significantly reduce PSE treatment requirements. An additional eight (10%) patients were improving but had to discontinue the drug due to side effects followed by progression. Therefore, they did not benefit from treatment. Although they were not included in our list of responders, their improvement has significance in emphasizing that the immunosuppressive properties of thalidomide may be better than what is suggested by our limited 20% response rate, and that the difficulty in dose escalating or maintaining patients on the medication due to side effects may be a major problem with this drug in the treatment of CGVHD.
A total of 29 (36%) of the 80 patients were taken off treatment because of side effects. Ten of these were unable to continue treatment due to sedation or constipatiotdabdorninal distension and three due to neuropathy. An additional 16 patients had skin rashes or neutropenia, which required discontinuing medication. Sedation, constipation, and neuropathy are well-described complications of thalidomide. In a report by Vogelsang et al,9 sedation and constipation did not apparently lead to difficulty in continuing treatment since they seemed to predominate only in the first weeks of therapy. Only 6 of 43 patients were withdrawn from that study because of drug side effects (4 because of neuropathy and 2 because of noncompliance with medication).
New skin rashes were not reported by Vogelsang et al. New skin rashes or exacerbation of previously existing skin CGVHD occurred in a significant number of our patients (13 of 80 or 16%) ( Table 4 ). The simplest explanation would be that these rashes represented a flare of CGVHD. However, we were impressed with the timing of the rash occumng soon after starting the drug, even in patients in whom PSEl CSA had not yet been tapered or who had had no skin CGVHD before starting thalidomide. In addition, two patients who were rechallenged had skin flare ups a second time. Two brief references to skin rashes as drug side effects in patients treated with thalidomide are noted in a review on the use of the drug for leprosy reaction.Ix." It is noteworthy that the patients in our study who developed skin rashes on thalidomide had more advanced CGVHD. It is possible that in some patients thalidomide may be initially causing a drugrelated skin reaction, which may then be exacerbating underlying subclinical or pre-existing skin CGVHD, just ab sun exposure has been reported to flare skin CGVHD.' This would explain the finding of histologic GVHD when skin biopsies were performed in these cases.
Neutropenia has not been reported as a side effect of thalidomide in the transplant literature.
There is a report from the World Health Organization on a tendency to neutropenia in leprosy patients treated with thalidomide.*" We observed a frequent association (14 of 80 patients) of neutropenia with the start of thalidomide therapy. In these cases it was not possible to differentiate the neutropenia from that occurring as a complication of CGVHD where multiple factors including infection, folatehtritional deficiency. or drug effects in addition to the probable autoimmune effects of GVHD on marrow function may have been active."." However, again the timing of this complication, occurring in the first weeks after thalidomide was started in patients without prior neutropenia, and the recurrence of neutropenia on rechallenge with thalidomide in six patients suggests this was a drug-related effect. Patients treated with thalidomide for CGVHD should have their blood counts frequently monitored during the first weeks of therapy.
We did not find thalidomide to be useful for treatment of the majority of patients with CGVHD, which was progressing after failing PSEKSA. We may have been limited by the high incidence of side effects (especially neutropenia and skin rashes) in this group, which did not allow for dose intensity. We did not measure drug levels in our patients but the majority did not tolerate escalating thalidomide doses above 400 to 600 mgld, which was below the target doses of 800 to 1,200 mgld. Vogelsang et al used doses of 800 to 1,600 mgld to reach target therapeutic serum levels." It is possible that if thalidomide were used earlier as part of first line therapy, patients would tolerate dose intensive therapy better with an improved response rate. Vogelsang et al' treated patients with poor risk features with thalidomide as part of first line therapy in combination with PSElCSA in their clinical trial. This led to an excellent response rate (7 of 21 patients had a CR) and improved survival (48%) compared with historical controls of However, the historical controls received PSE or PSEhzathioprine and did not uniformly receive CSA. Sullivan et a12.'4.25 found combined PSElCSA also improved survival to an equivalent level of 50% compared with 26% over PSE or CSA as single agents for CGVHD patients with poor risk defined by thrombocytopenia. Therefore, the true response and survival benefit of adding thalidomide to PSElCSA as first line therapy for CGVHD needs to be studied in a randomized trial.
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